Trials / Completed
CompletedNCT00088114
STA-4783 and Paclitaxel for Treatment of Solid Tumors
A Phase I Trial of STA-4783 in Patients Receiving Paclitaxel for Treatment of Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (planned)
- Sponsor
- Synta Pharmaceuticals Corp. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, toxicity and maximum tolerated dose of single doses of STA-4783/paclitaxel in combination when administered intravenously to patients with refractory cancer. To determine the pharmacokinetics of STA-4783 and paclitaxel when co-administered. To assess the anti-tumor activity of STA-4783 and paclitaxel when co-administered.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | STA-4783/paclitaxel |
Timeline
- Start date
- 2003-01-01
- Primary completion
- 2004-10-01
- Completion
- 2004-10-01
- First posted
- 2004-07-21
- Last updated
- 2014-03-06
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00088114. Inclusion in this directory is not an endorsement.